According to the report, the global myasthenia gravis market was valued at US$ 1.2 Bn in 2018 and is anticipated to expand at a CAGR of 8.0% from 2019 to 2030
The global myasthenia gravis market for the historical period 2018–2019 and forecast period 2020–2030, high prevalence of autoimmune diseases and strong focus on introducing new therapies is augmenting the growth of global myasthenia gravis market. Moreover, improving healthcare infrastructure is likely boost the growth of global myasthenia gravis market during the forecast period.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111875
To know the scope of our report Get a Sample on Myasthenia Gravis Market
Rise in Focus on Research & Development and Increase in Prevalence of Autoimmune Disorder: Key Drivers of Global Myasthenia Gravis Market
Autoimmune disorder is a condition of immune system in which the body’s immune system attacks healthy cells. It is most common in the older men (over 60) and young adult women (under 40). Hence, increase in geriatric population is a key factor likely boost the growth of market. For instance, according to Cancer Facts & Figures 2019, estimated number of older adults age 85 years and above was 6.4 million in 2016 and it is expected to reach 19.0 million by 2060
Myasthenia gravis (MG) is an autoimmune neuromuscular disorder that affects voluntary muscles. According to the Myasthenia Gravis Foundation of America, around 20 in 100,000 people in the U.S. are diagnosed with myasthenia gravis each year
Myasthenia gravis is a rare disease without a definite cure, however it can be treated with medications, surgeries, and other therapies alone or in combination. This is augmenting the demand for new therapies and medications, which is driving key players operating in the market to invest in the research and development and develop new therapies. For instance, Rozanolixizumab (UCB7665) is a humanized anti-human neonatal Fc receptor (FcRn) monoclonal antibody designed to reduce the levels of pathogenic IgG in autoimmune diseases. It is in clinical trial phase for reducing the levels of pathogenic IgG in autoimmune diseases and myasthenia gravis. Strong pipeline and introduction of new therapies are the factors likely boost the growth of myasthenia gravis market
Increase in Healthcare Infrastructure Propel Global Myasthenia Gravis Market Growth
Increase in health care expenditure coupled with rise in global per capita income is anticipated to drive demand for costly treatments such as plasma exchange and intravenous immunoglobulin (IVIG) therapies
Moreover, governments in developing countries are making significant investments toward modernization of health care infrastructure, which is likely to increase access to health care. This is expected to increase in the demand for advance technologies, therapies and treatments. This is leading to create opportunities in the monoclonal antibodies and IVIG treatments in the myasthenia gravis market in the near future
Expensive Treatment Options to Hamper Global Myasthenia Gravis Market
Discovery and development of new therapeutics incurs high cost and takes longer time for commercialization. The never approved therapies with IVIG and monoclonal antibodies are expensive treatment options. The cost of plasma collection and manufacturing processes for IVIG products is high as compared to the materials and processes used in the manufacture of traditional pharmaceutical products. Moreover, being a blood derived component, highly sophisticated collection, purification, and storage methods are required for intravenous immunoglobulin (IVIG) products.
Plasmapheresis and thymectomy are costly in comparison to symptomatic drug therapy which additionally need hospitalization. Cost is major factor that influence the selection of treatment which is anticipated to hamper the growth of global myasthenia gravis treatment market.
Chronic Side Effects: Restrain of Global Myasthenia Gravis Market
Side effects associated with intravenous immunoglobulin (IVIG) preparations could present serious health problems in some patients. Some of the side effects associated with intravenous immunoglobulin (IVIG) are flushing, muscle cramps, chills, fever, nausea, vomiting, back/joint pain, chest pain, sudden cough, wheezing, or shortness of breath.
View full report@ https://qyresearchmedical.com/report/myasthenia-gravis-market-treatment-drug-treatment-cholinesterase-inhibitors-monoclonal-antibodies-and-chronic-immunomodulators-and-rapid-immunotherapies-plasmapheresis-intravenous-immunoglobulin-ivlg-and-019-2030/111875
These side effects can sometimes force a patient to discontinue the therapy which are leading to restrain the global myasthenia gravis market.
Global Myasthenia Gravis Market: Competitive Landscape
This report profiles major players in the global myasthenia gravis market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
The global myasthenia gravis market is highly fragmented, with the presence of a number of international as well as regional players
Leading players operating in the global myasthenia gravis market are
- Alexion Pharmaceutical Inc.
- Avadel Pharmaceuticals, PLC. (Flamel Technologies)
- CSL Behring
- Grifols, S.A.
- Baxter International, Inc.
- Shire plc
- Novartis AG
- F. Hoffmann-La Roche AG
- Takeda Pharmaceutical Company Limited
- Valeant Pharmaceuticals International, Inc.
Key Questions Answered in Global Myasthenia Gravis Market Report
- What is the scope of growth for product companies in the global myasthenia gravis market?
- What will be the Y-o-Y growth of the global myasthenia gravis market between 2019 and 2027?
- What is the influence of changing trends in technologies on the global myasthenia gravis market?
- Will North America continue to be the most profitable market for myasthenia gravis providers?
- Which factors are anticipated to hamper the growth of the global myasthenia gravis market during the forecast period?
- Which are the leading companies in the global myasthenia gravis market?
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111875/2900
Global Myasthenia Gravis Market – Segmentation
- Drug Treatment
- Cholinesterase Inhibitors
- Chronic Immunomodulators
- Monoclonal Antibodies
- Rapid Immunotherapies
- Intravenous Immunoglobulin (Ivlg)
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
TABLE OF CONTENT
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Myasthenia Gravis Market
4. Market Overview
4.1.1. Treatment Type Definition
4.1.2. Industry Evolution / Developments
4.3. Market Dynamics
4.4. Global Myasthenia Gravis Market Analysis and Forecasts, 2017–2030
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Industry Development (Acquisition, Collaboration, Merger, Approvals etc.)
5.3. Epidemiology of Myasthenia Gravis By Country/Sub-region
5.4. Regulatory Scenario
6. Global Myasthenia Gravis Market Analysis and Forecasts, by Treatment Type
6.1. Introduction & Definition
6.1.1. Key Findings / Developments
6.2. Global Myasthenia Gravis Market Value & Volume Forecast by Treatment Type, 2017–2030
6.2.1. Drug Treatment
188.8.131.52. Cholinesterase Inhibitors
184.108.40.206. Chronic Immunomodulators
220.127.116.11. Monoclonal Antibodies
6.2.2. Rapid Immunotherapies
18.104.22.168. Intravenous Immunoglobulin (Ivlg)
6.3. Global Myasthenia Gravis Market Attractiveness by Treatment Type
7. Global Myasthenia Gravis Market Analysis and Forecasts, by Region
7.1. Key Findings
7.2. Global Myasthenia Gravis Market Value & Volume Forecast by Region
7.2.1. North America
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. Global Myasthenia Gravis Market Attractiveness by Country/Region
8. North America Myasthenia Gravis Market Analysis and Forecast
8.1.1. Key Findings
8.2. North America Myasthenia Gravis Market Value & Volume Forecast by Treatment Type, 2017–2030
8.2.1. Drug Treatment
22.214.171.124. Cholinesterase Inhibitors
126.96.36.199. Chronic Immunomodulators
188.8.131.52. Monoclonal Antibodies
8.2.2. Rapid Immunotherapies
184.108.40.206. Intravenous Immunoglobulin (Ivlg)
8.3. North America Myasthenia Gravis Market Value & Volume Forecast by Country, 2017–2030
8.4. North America Myasthenia Gravis Market Attractiveness Analysis
8.4.1. By Treatment Type
8.4.2. By Country
9. Europe Myasthenia Gravis Market Analysis and Forecast
9.1.1. Key Findings
9.2. Europe Myasthenia Gravis Market Value & Volume Forecast by Treatment Type, 2017–2030
9.2.1. Drug Treatment
220.127.116.11. Cholinesterase Inhibitors
18.104.22.168. Chronic Immunomodulators
22.214.171.124. Monoclonal Antibodies
9.2.2. Rapid Immunotherapies
126.96.36.199. Intravenous Immunoglobulin (Ivlg)
9.3. Europe Myasthenia Gravis Market Value & Volume Forecast by Country/Sub-region, 2017–2030
9.3.6. Rest of Europe
9.4. Europe Myasthenia Gravis Market Attractiveness Analysis
9.4.1. By Treatment Type
9.4.2. By Country/Sub-region
10. Asia Pacific Myasthenia Gravis Market Analysis and Forecast
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111875/2900
You can place an order or ask any questions, please feel free to contact firstname.lastname@example.org | +1 9197 992 333
QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.
For Latest Update Follow Us: